Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus.

Autor: Bing SJ; Division of Gene Therapy 2, Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Seirup M; Promega Corporation, Madison, WI, USA., Hoang TT; Promega Corporation, Madison, WI, USA., Najera SS; Division of Gene Therapy 2, Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Britten C; Waters | Wyatt Technology, Santa Barbara, CA, USA., Warrington SL; Division of Gene Therapy 2, Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Chu SL; Division of Gene Therapy 2, Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Mazor R; Division of Gene Therapy 2, Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. ronit.mazor@fda.hhs.gov.

Publikováno v: Nature biomedical engineering [Nat Biomed Eng] 2024 Feb; Vol. 8 (2), pp. 193-200. Date of Electronic Publication: 2023 Nov 23.